Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,300

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

HypercholesterolemiaHyperlipidemia

Interventions

DRUG

niacin (+) laropiprant

Duration of Treatment: 18 Weeks

DRUG

niacin

Duration of Treatment: 18 Weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00378833 - Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) | Biotech Hunter | Biotech Hunter